Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Pui Lee, MD;PhD
Boston Children's Hospital
Newton, Massachusetts, United States
Disclosure information not submitted.
Susan Shenoi, MS, MBBS, RhMSUS
Seattle Children's Hospital and Research Center
Mercer Island, WA, WA, United States
Disclosure(s): Amgen: Consultant (Terminated, February 14, 2023); Novartis: Consultant (Terminated, August 1, 2023); pfizer: Consultant (Ongoing)
Systemic juvenile idiopathic arthritis (SJIA) is characterized by daily fever, evanescent skin rash, and chronic arthritis. SJIA has the greatest mortality and morbidity among the different subtypes of JIA. Biologic DMARDs that target IL-1 and IL-6 effectively control the inflammation in SJIA and have become the mainstay of therapy. However, the use of these biologic medications is associated with the increase incidence of SJIA-associated lung disease. While our understanding of this potentially fatal complication remains incomplete, the use of biologic DMARDs in patients with SJIA, especially those with early features of lung disease, has become a topic of controversy. Two speakers will discuss available data on the development of lung disease and debate the benefits for continuing versus withholding biologic DMARDs targeting the IL-1 and IL-6 pathways.
Interactive Speaker: Karen Onel, MD – HSS
Interactive Speaker: Randy Cron, MD,PhD – University of Alabama at Birmingham